Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
4.48
Dollar change
-0.01
Percentage change
-0.22
%
IndexRUT P/E- EPS (ttm)-1.50 Insider Own24.32% Shs Outstand120.71M Perf Week-6.86%
Market Cap543.42M Forward P/E- EPS next Y-0.71 Insider Trans-0.23% Shs Float91.80M Perf Month-7.63%
Income-171.67M PEG- EPS next Q-0.18 Inst Own71.11% Short Float9.51% Perf Quarter96.49%
Sales36.85M P/S14.75 EPS this Y56.12% Inst Trans4.10% Short Ratio3.75 Perf Half Y258.40%
Book/sh0.31 P/B14.65 EPS next Y-9.10% ROA-61.27% Short Interest8.73M Perf Year9.27%
Cash/sh1.72 P/C2.60 EPS next 5Y- ROE-266.24% 52W Range0.80 - 9.62 Perf YTD93.10%
Dividend Est.- P/FCF- EPS past 5Y11.93% ROI-263.08% 52W High-53.43% Beta1.48
Dividend TTM- Quick Ratio3.36 Sales past 5Y12371.94% Gross Margin95.88% 52W Low459.02% ATR (14)0.41
Dividend Ex-Date- Current Ratio3.36 EPS Y/Y TTM31.64% Oper. Margin-463.86% RSI (14)45.00 Volatility7.39% 8.99%
Employees123 Debt/Eq0.92 Sales Y/Y TTM38.65% Profit Margin-465.80% Recom1.50 Target Price6.57
Option/ShortYes / Yes LT Debt/Eq0.77 EPS Q/Q63.57% Payout- Rel Volume0.60 Prev Close4.49
Sales Surprise-27.40% EPS Surprise0.12% Sales Q/Q-27.14% EarningsFeb 28 BMO Avg Volume2.33M Price4.48
SMA20-14.35% SMA506.20% SMA20070.98% Trades Volume1,397,862 Change-0.22%
Date Action Analyst Rating Change Price Target Change
Mar-19-24Upgrade JP Morgan Underweight → Neutral $5
Feb-29-24Upgrade Wedbush Neutral → Outperform $2 → $7
Feb-29-24Upgrade Guggenheim Neutral → Buy $7
Feb-29-24Upgrade BTIG Research Neutral → Buy $6
Dec-04-23Upgrade Citigroup Neutral → Buy $1 → $5
Jul-28-23Downgrade Robert W. Baird Outperform → Neutral $7 → $1
Jul-27-23Downgrade Wedbush Outperform → Neutral
Jul-27-23Downgrade Truist Buy → Hold
Jul-27-23Downgrade JP Morgan Neutral → Underweight
Jul-27-23Downgrade Guggenheim Buy → Neutral
Feb-29-24 08:41AM
Feb-28-24 09:49PM
08:10AM
07:35AM
07:00AM
08:01AM Loading…
Feb-27-24 08:01AM
Feb-21-24 08:00AM
Feb-20-24 10:00AM
Feb-01-24 08:00AM
Jan-05-24 08:01AM
Dec-01-23 04:30PM
Nov-08-23 02:42PM
12:13AM
Nov-07-23 08:10AM
07:00AM
04:30PM Loading…
Oct-31-23 04:30PM
08:00AM
Sep-07-23 06:30AM
Sep-06-23 07:00AM
Aug-18-23 09:35AM
Aug-16-23 09:35AM
Aug-08-23 09:40AM
08:00AM
Aug-04-23 04:05PM
Jul-28-23 10:13AM
03:14AM
Jul-27-23 09:34PM
01:44PM
07:06AM
Jul-13-23 09:45AM
04:05PM Loading…
Jul-06-23 04:05PM
Jun-22-23 11:04AM
Jun-16-23 10:43AM
02:26AM
Jun-15-23 09:32AM
07:36AM
07:30AM
Jun-13-23 06:00AM
Jun-02-23 04:05PM
May-28-23 09:06AM
May-24-23 08:00AM
May-09-23 08:35AM
07:00AM
May-04-23 04:05PM
May-03-23 08:00AM
May-02-23 08:00AM
Apr-26-23 04:05PM
Apr-19-23 02:42PM
Apr-17-23 11:07AM
Apr-06-23 04:05PM
Apr-05-23 02:00PM
Mar-16-23 11:20AM
Mar-13-23 02:00PM
07:54AM
07:30AM
Mar-10-23 07:10PM
Mar-03-23 04:05PM
Mar-02-23 08:55PM
Mar-01-23 05:24AM
Feb-28-23 11:51PM
07:00AM
Feb-21-23 08:00AM
Feb-03-23 04:05PM
Feb-02-23 08:00AM
Feb-01-23 08:00AM
Jan-25-23 08:00AM
Jan-20-23 03:16PM
Jan-16-23 02:18AM
Jan-06-23 04:05PM
07:00AM
Dec-31-22 07:42AM
Dec-23-22 12:46PM
10:08AM
Dec-22-22 04:08PM
04:05PM
Dec-14-22 08:00AM
Dec-02-22 04:05PM
Nov-08-22 08:00AM
Nov-07-22 08:25AM
07:00AM
Nov-04-22 04:05PM
Oct-31-22 08:00AM
Oct-30-22 10:13AM
Oct-17-22 09:40AM
Oct-06-22 04:05PM
Oct-04-22 04:05PM
Sep-30-22 08:02AM
Sep-12-22 08:00AM
Sep-06-22 08:00AM
Sep-02-22 04:05PM
Sep-01-22 10:17AM
Aug-16-22 09:55AM
08:00AM
Aug-12-22 06:05AM
Aug-11-22 11:25AM
Aug-09-22 06:58AM
Aug-08-22 05:15PM
04:04PM
04:02PM
Aug-04-22 04:05PM
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Protopapas AnnaDirectorJan 16 '24Sale2.7129,39979,671125,153Jan 17 05:21 PM
Lowinger Timothy BSVP, Chief Sci.&Tech. OfficerJan 16 '24Sale2.7110,40928,208199,329Jan 17 05:19 PM
DeSchuytner BrianSVP, COO & CFOJan 16 '24Sale2.719,32725,27654,511Jan 17 05:18 PM
Mandelia AshishVP, Chief Accounting OfficerJan 16 '24Sale2.715,02513,61823,328Jan 17 05:20 PM
Carvajal AlejandraSVP, Chief Legal OfficerJan 16 '24Sale2.714,38111,87327,403Jan 17 05:18 PM
Bala MohanSVP, Chief Development OfficerJan 16 '24Sale2.713,4319,29814,052Jan 17 05:16 PM
MISRA TUSHARSVP, Chief Manuf. OfficerJan 16 '24Sale2.713,3579,09717,966Jan 17 05:21 PM
Lowinger Timothy BSVP, Chief Sci.&Tech. OfficerJan 15 '24Option Exercise0.0015,2080209,738Jan 17 05:19 PM
DeSchuytner BrianSVP, COO & CFOJan 15 '24Option Exercise0.0010,208063,838Jan 17 05:18 PM
Protopapas AnnaDirectorJan 15 '24Option Exercise0.0038,9580154,552Jan 17 05:21 PM
Mandelia AshishVP, Chief Accounting OfficerJan 15 '24Option Exercise0.005,352028,353Jan 17 05:20 PM
Mandelia AshishVP, Chief Accounting OfficerJan 14 '24Option Exercise0.004,783023,001Jan 17 05:20 PM
MISRA TUSHARSVP, Chief Manuf. OfficerJan 14 '24Option Exercise0.001,458021,323Jan 17 05:21 PM
Protopapas AnnaDirectorJan 14 '24Option Exercise0.0016,7500115,594Jan 17 05:21 PM
Carvajal AlejandraSVP, Chief Legal OfficerJan 14 '24Option Exercise0.002,500031,784Jan 17 05:18 PM
DeSchuytner BrianSVP, COO & CFOJan 14 '24Option Exercise0.006,250055,630Jan 17 05:18 PM
Lowinger Timothy BSVP, Chief Sci.&Tech. OfficerJan 14 '24Option Exercise0.004,7920194,530Jan 17 05:19 PM
Lowinger Timothy BSVP, Chief Sci.&Tech. OfficerJan 13 '24Option Exercise0.009,3750189,738Jan 17 05:19 PM
DeSchuytner BrianSVP, COO & CFOJan 13 '24Option Exercise0.0010,000047,380Jan 17 05:18 PM
Carvajal AlejandraSVP, Chief Legal OfficerJan 13 '24Option Exercise0.008,958029,284Jan 17 05:18 PM
Bala MohanSVP, Chief Development OfficerJan 13 '24Option Exercise0.008,750017,483Jan 17 05:16 PM
Protopapas AnnaDirectorJan 13 '24Option Exercise0.0031,250098,844Jan 17 05:21 PM
MISRA TUSHARSVP, Chief Manuf. OfficerJan 13 '24Option Exercise0.007,083019,865Jan 17 05:21 PM
Mandelia AshishVP, Chief Accounting OfficerJan 13 '24Option Exercise0.002,645018,218Jan 17 05:20 PM
Bala MohanSVP, Chief Development OfficerOct 26 '23Sale1.131,9122,1618,733Oct 27 04:07 PM
Bala MohanSVP, Chief Development OfficerOct 25 '23Option Exercise0.006,250010,645Oct 27 04:07 PM
MISRA TUSHARSVP, Chief Manuf. OfficerAug 17 '23Sale1.181,9082,25111,507Aug 18 04:01 PM
MISRA TUSHARSVP, Chief Manuf. OfficerAug 16 '23Option Exercise0.006,250013,415Aug 18 04:01 PM
Carvajal AlejandraSVP, Chief Legal OfficerApr 27 '23Sale3.893,94415,34220,326Apr 28 04:15 PM
Carvajal AlejandraSVP, Chief Legal OfficerApr 26 '23Option Exercise0.0013,250024,270Apr 28 04:15 PM